Scynexis, Inc.
A biotechnology company in Jersey City, New Jersey, that develops medicines for hard-to-treat infections and rare diseases. Its best-known product is Brexafemme, an oral pill for vaginal yeast infections that was the first new class of antifungal drug approved by the FDA in more than twenty years. The company began in 1999 as a chemistry-and-automation services firm called ScyRex, later renamed SCYNEXIS, and today also works on treatments for polycystic kidney disease.
Sold 599.0K
Granted 1.33M · Bought 246.0K
Bought 900.0K
Granted 656.7K · Bought 8.1K
Granted 381.0K
Granted 87.2K · Bought 801.7K
Bought 10.0K
Bought 50.0K
Bought 50.0K
Bought 28.0K
Granted 66.0K · Bought 4.0K
Bought 40.0K
Granted 58.2K
Bought 20.0K
Granted 68.9K · Bought 48.0K
Granted 68.9K · Bought 8.0K
Granted 68.9K · Bought 5.0K
Granted 125.0K · Bought 21.5K
Granted 68.9K · Bought 7.4K
Granted 68.9K · Bought 31.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Edelman Joseph +2 co-filers10% owner · 4 transactions | — | 4.23Mas of Jan 2021 | — | — | 599.0K |
| Angulo Gonzalez DavidChief Executive Officer, Director · 26 transactions | — | 1.36M | 1.33M | 246.0K | — |
| Alta Biopharma Management II LLC +3 co-filers10% owner · 14 transactions | — | 1.25Mas of May 2014 | — | 900.0K | — |
| Sukenick ScottChief Legal Officer · 13 transactions | — | 574.5K | 656.7K | 8.1K | — |
| Macleod ivorChief Financial Officer · 4 transactions | — | 398.5K | 381.0K | — | — |
| Taglietti MarcoChief Executive Officer, Director · 33 transactions | — | 272.1Kas of Apr 2022 | 87.2K | 801.7K | — |
| F.C.P.R. Genavent10% owner · 8 transactions | — | 210.9Kas of May 2014 | — | 10.0K | — |
| Nothias Jean-YvesDirector · 8 transactions | — | 172.2Kas of May 2014 | — | 50.0K | — |
| FCPR Biotechnology Fund10% owner · 8 transactions | — | 83.4Kas of May 2014 | — | 50.0K | — |
| Ventech Capital II10% owner · 8 transactions | — | 71.7Kas of May 2014 | — | 28.0K | — |
| Gilman Steven CDirector · 5 transactions | — | 70.0Kas of Jun 2025 | 66.0K | 4.0K | — |
| Machado PatrickDirector · 1 transaction | — | 60.0Kas of Sep 2016 | — | 40.0K | — |
| Coyne ChristineChief Commercial Officer · 2 transactions | — | 58.2Kas of Feb 2022 | 58.2K | — | — |
| Machado Clarence PatrickDirector · 1 transaction | — | 20.0Kas of Jun 2016 | — | 20.0K | — |
| Kirby Pamela JDirector · 2 transactions | — | 12.7Kas of May 2014 | — | — | — |
| Macdonald GuyDirector · 7 transactions | — | 12.6K | 68.9K | 48.0K | — |
| Tinmouth Brian PhilippeDirector · 6 transactions | — | 12.1K | 68.9K | 8.0K | — |
| Anido ArmandoDirector · 6 transactions | — | 11.8K | 68.9K | 5.0K | — |
| Francois EricChief Financial Officer · 6 transactions | — | 11.7Kas of Dec 2020 | 125.0K | 21.5K | — |
| Hanham AnnDirector · 7 transactions | — | 11.6K | 68.9K | 7.4K | — |
| Hastings David CDirector · 7 transactions | — | 11.5K | 68.9K | 31.8K | — |
| Langlois PatrickDirector · 2 transactions | — | 10.5Kas of May 2014 | — | — | — |
| Arthaud LaurentDirector · 5 transactions | — | 9.7Kas of May 2014 | — | — | — |
| Ribeill Yves JPresident and CEO, Director · 2 transactions | — | 1.2Kas of May 2014 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +1.68M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.